Effectiveness and Acceptability of Stellate Ganglion Block for Posttraumatic Stress Disorder Symptoms

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

113 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-05-25

Study Completion Date

2018-06-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a multisite, randomized, blinded, sham-procedure-controlled study to evaluate the efficacy of right-sided stellate ganglion block (SGB) on the acute symptomatology of Post traumatic Stress Disorder (PTSD), evaluated by the Clinician-Administered PTSD Scale (CAPS-5) clinical interview at pre-treatment and at 8 weeks. This entry describes the effectiveness study.The acceptability study is described in a separate entry.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effectiveness and Acceptability of Stellate Ganglion Block for Posttraumatic Stress Disorder Symptoms - Acceptability

NCT03302312

Posttraumatic Stress Disorder

COMPLETED

Augmenting Massed Prolonged Exposure With a Stellate Ganglion Block to Treat PTSD

NCT04302181

Stress Disorders, Post-Traumatic

COMPLETED EARLY_PHASE1

Stellate Ganglion Block in the Treatment of Posttraumatic Stress Disorder

NCT05427500

PTSD

ENROLLING_BY_INVITATION PHASE3

Combining Stellate Ganglion Block With Prolonged Exposure for PTSD

NCT05889741

Stress Disorders, Post-Traumatic

RECRUITING PHASE2

Effects of Stellate Ganglion Block in Post-traumatic Stress Disorder

NCT05391971

Post Traumatic Stress Disorder

RECRUITING PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study intervention will be administered at week 0 and at week 2. Injections will be performed under ultrasound visualization. The study medication will be either 7-10 mL 0.5% ropivacaine injected ventral to the right longus coli muscle (around and into the ventral fascia) and into the longus coli immediately dorsal to the presumed ventral fascia at the level of the C6 anterior tubercle (landmarks for the stellate ganglion) (active study medication) or 1-2 mL preservative free normal saline injected anterolateral to the anterior tubercle of C6 (sham procedure). The participant will not be informed which treatment he or she has received and the interaction of the participant and treating physician will be scripted as much as possible. Following the intervention, the treating physician should have no further contact with the participant except as required for participant safety.

Participants will be evaluated for posttraumatic stress disorder (PTSD) symptomatology prior to week 0 and at 8 weeks using the Diagnostic and Statistical Manual (DSM-5) Clinician-Administered PTSD Scale (CAPS-5). They will complete the PTSD Checklist for DSM-5 (PCL-5), the PTSD Checklist - Civilian Version (PCL-C), and the Mini-international Neuropsychiatric Interview (M.I.N.I.-Plus) Suicidality Items at 0, 2, 4, 6, and 8 weeks; they also will complete the M.I.N.I.-Plus items at screening. The 12 item short form survey (SF-12), generalized anxiety disorder 7-item (GAD-7), patient health questionnaire (PHQ-9), K6, Alcohol Use Disorder Identification Test (AUDIT-C/AUDIT), and a short pain scale will be completed at weeks 0, 4, and 8.

Data collected at baseline and 8 weeks will be the primary focus of data analysis. Data collected at other time points will be analyzed as appropriate.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

PostTraumatic Stress Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Participants will be centrally randomized to 2:1 active:sham SGB and will be evaluated at Womack Army Medical Center in North Carolina, Tripler Army Medical Center in Hawaii, and Landstuhl Regional Medical Center in Germany. Randomization will be stratified by site so that each will have a 2:1 active:sham ratio. The target population includes active-duty service members and study duration is 10 weeks in the clinical effectiveness trial for which an enrollment of 240 participants is planned.

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Stellate Ganglion Block (SGB)

7-10 mL 0.5% ropivacaine injected under ultrasound visualization ventral to right longus coli muscle (around and into the ventral fascia) and into the longus coli immediately dorsal to the presumed ventral fascia, at the level of the C6 anterior tubercle (landmarks for stellate ganglion).

Group Type ACTIVE_COMPARATOR

Ropivacaine

Intervention Type DRUG

0.5% ropivacaine

Sham Treatment

1-2 mL preservative-free normal saline, injected under ultrasound visualization anterolateral to right anterior tubercle of C6.

Group Type SHAM_COMPARATOR

Sham treatment

Intervention Type DRUG

preservative-free normal saline

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ropivacaine

0.5% ropivacaine

Intervention Type DRUG

Sham treatment

preservative-free normal saline

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Naropin saline

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Member of the Army on active duty status
* Personal access to Internet
* Anticipated stable assignment to installation for at least 2 months
* Stable dosing for ≥3 months, if receiving psychotropic medications
* Prior to enrollment, offered PTSD treatment using A-level modality (as defined by U.S. Army Medical Command (MEDCOM) policy 14-094; 18 Dec 2014).
* PTSD Checklist - Civilian (PCL-C) score of 32 or greater at screening
* Acceptable clinically indicated preoperative laboratory studies, per standard site-specific protocols

Exclusion Criteria

* Prior Stellate Ganglion Block (SGB)
* Allergy to amide local anesthetics (e.g., ropivacaine, bupivacaine)
* Pregnancy (evaluated by urine test pre-procedure)
* Current anticoagulant use
* History of a bleeding disorder
* Infection or mass at injection site
* Myocardial infarction within 6 months of procedure
* Phrenic or laryngeal nerve palsy (hoarseness)
* History of glaucoma
* History of schizophrenia, other psychotic disorder, bipolar disorder, or personality disorder (axis 2)
* Moderate or severe traumatic brain injury
* Symptoms of moderate to severe substance use disorder in past 30 days
* Suicidal ideation in the past 2 months, documented by the M.I.N.I.-Plus Suicidality Items
* Any ongoing other major life stressor or condition not listed here that the site Investigator believes clearly would place the participant at risk for injury or a poor outcome

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No